Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-MPS vs cyclophosphamide for remission induction in microscopic polyangiitis
ChiCTR2200063823Phase 4Not yet recruiting
- Sponsor
- Shanxi Medical University Second Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium in microscopic polyangiitis (MPA) (2 arms), sponsored by Shanxi Medical University Second Hospital. Primary endpoint: Complete remission rate at 6 months with oral EC-MPS. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on ChiCTR2200063823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063823.